HPS-099 - Low monitoring rate of hematologic adverse effects in sulfasalazine users: A retrospective study in a Northern Taiwan medical center

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-099
• By: HUNG, Chia-Wen (Department of Pharmacy, Cathay General Hospital, Taiwan)
• Co-author(s): Ms Chia-Wen Hung (Department of Pharmacy, Cathay General Hospital, Taipei, Taiwan / Taipei Pharmacists Association, Taipei, Taiwan)
  Ms Chun-Ju Wang (Department of Pharmacy, Cathay General Hospital, Taipei, Taiwan / Taipei Pharmacists Association, Taipei, Taiwan)
  Ms Chi-Lan Kao (Department of Pharmacy, Cathay General Hospital, Taipei, Taiwan / Taipei Pharmacists Association, Taipei, Taiwan)
  
• Abstract:

  Background
  Sulfasalazine is a disease-modifying anti-rheumatic drug (DMARD) widely used to treat rheumatologic and inflammatory conditions. However, serious hematologic adverse drug reactions (ADRs), including bone marrow suppression and leukopenia, have been reported in Taiwan. These adverse effects typically occur within the first three months..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login